Preventing liver recurrence after partial hepatectomy for intrahepatic cholangiocarcinoma using adjuvant hepatic arterial infusion pump chemotherapy – PUMP IV trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513726-33-00

Acronym

PUMP IV

Enrollment

Registered

2024-08-05

Start date

2024-10-25

Completion date

Unknown

Last updated

2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic cholangiocarcinoma (iCCA)

Brief summary

Two-year hepatic recurrence free survival (hRFS)

Detailed description

Overall recurrence free survival (RFS), Overall survival (OS), Postoperative complications, Chemotherapy related adverse events (AEs), Proportion of patients that started with adjuvant HAIP chemotherapy, Quality of life, Cost-effectiveness, Predictive biomarkers for the efficacy of HAIP chemotherapy

Interventions

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Two-year hepatic recurrence free survival (hRFS)	—

Secondary

Measure	Time frame
Overall recurrence free survival (RFS), Overall survival (OS), Postoperative complications, Chemotherapy related adverse events (AEs), Proportion of patients that started with adjuvant HAIP chemotherapy, Quality of life, Cost-effectiveness, Predictive biomarkers for the efficacy of HAIP chemotherapy	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026